JOURNAL ARTICLE

CDC funds controversial hepatitis B vaccine trial in African newborns: Scientists question the value of the proposed study, which will investigate a vaccine long known to be efficacious and safe.

Published In: Sciencemag.org, 2025. P. N.PAG 1 of 3
Database: Applied Science & Technology Source Ultimate 2 of 3
Authored By: Offord, Catherine 3 of 3

Abstract

The article discusses a $1.6 million study funded by the U.S. Centers for Disease Control and Prevention (CDC) to investigate the health outcomes of hepatitis B vaccination in newborns in Guinea-Bissau. Public health scientists have raised ethical concerns about the necessity and design of the study, given that the hepatitis B vaccine is already known to be safe and effective. Critics argue that conducting a randomized controlled trial on a well-established vaccine may not yield useful insights and could be ethically questionable. The study, led by researchers from the University of Southern Denmark, aims to assess the timing and delivery of the vaccine, but skepticism remains regarding its potential contributions to public health policy. [Extracted from the article]

Additional Information

Source:Sciencemag.org. 2025/12, pN.PAG
Document Type:Article
Subject Area:Health and Medicine
Publication Date:2025
Accession Number:190405171
Copyright Statement:Copyright of Sciencemag.org is the property of American Association for the Advancement of Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.